Sign In

Login

Password

Forgot Password ? Sign Up

Ibogain (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ibogain" in German language version.

refsWebsite
Global rank German rank
13nih.gov
4th place
7th place
7doi.org
2nd place
3rd place
7espacenet.com
800th place
160th place
5web.archive.org
1st place
1st place
2ibogainedossier.com
low place
low place
1sigmaaldrich.com
924th place
87th place
1puzzlepiece.org
low place
low place
1ibogainealliance.org
low place
low place
1redirecter.toolforge.org
33rd place
2nd place
1maps.org
low place
low place
1biopsychiatry.com
low place
low place
1faz.net
240th place
13th place
1spektrum.de
1,960th place
130th place
1lovdata.no
5,131st place
4,715th place

biopsychiatry.com

doi.org

  • C. Frauenfelder: Neuer Zugang zu den Iboga-Alkaloiden. Zürich 1999, S. 24, doi:10.3929/ethz-a-003839200 (Dissertation, ETH Zürich).
  • Koenig X, Kovar M, Boehm S, Sandtner W, Hilber K: Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. In: Addict Biol. 2012, doi:10.1111/j.1369-1600.2012.00447.x, PMID 22458604.
  • Alper K, Reith ME, Sershen H: Ibogaine and the inhibition of acetylcholinesterase. In: J Ethnopharmacol. 139. Jahrgang, Nr. 3, 2012, S. 879–82, doi:10.1016/j.jep.2011.12.006, PMID 22200647.
  • Dao-Yao He, Nancy N. H. McGough, Ajay Ravindranathan, Jerome Jeanblanc, Marian L. Logrip, Khanhky Phamluong, Patricia H. Janak, Dorit Ron: Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption. In: Journal of Neuroscience. Band 25, Nr. 3, 2005, S. 619–628, doi:10.1523/JNEUROSCI.3959-04.2005, PMID 15659598.
  • Hoelen DW, Spiering W, Valk GD: Long-QT syndrome induced by the antiaddiction drug ibogaine. In: N. Engl. J. Med. 360. Jahrgang, Nr. 3, 2009, S. 308–9, doi:10.1056/NEJMc0804248, PMID 19144953.
  • Bulling S, Schicker K, Zhang YW, et al.: The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. In: J. Biol. Chem. 287. Jahrgang, Nr. 22, 2012, S. 18524–34, doi:10.1074/jbc.M112.343681, PMID 22451652, PMC 3365767 (freier Volltext).
  • Bowen WD, Vilner BJ, Williams W, Bertha CM, Kuehne ME, Jacobson AE: Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity. In: Eur J Pharmacol. 279. Jahrgang, Nr. 1, 1995, S. R1–3, doi:10.1016/0014-2999(95)00247-i, PMID 7556375.

espacenet.com

worldwide.espacenet.com

  • Patent EP0163697B1: Schnelles Verfahren zur Unterbrechung des Gewöhnungssyndroms für Narkotika. Angemeldet am 13. November 1984, veröffentlicht am 23. Mai 1990, Erfinder: Howard S. Lotsof.‌
  • Patent US4587243A: Rapid method for interrupting the cocaine and amphetamine abuse syndrome. Angemeldet am 15. Juli 1985, veröffentlicht am 6. Mai 1986, Erfinder: Howard S. Lotsof.‌
  • Patent US4857523A: Rapid method for attenuating the alcohol dependency syndrome. Angemeldet am 18. Juli 1988, veröffentlicht am 15. August 1989, Anmelder: NDA International Inc, Erfinder: Howard S. Lotsof.‌
  • Patent US5026697A: Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome. Angemeldet am 30. Mai 1990, veröffentlicht am 25. Juni 1991, Anmelder: NDA International Inc, Erfinder: Howard S. Lotsof.‌
  • Patent EP0511325A4: Schnelles Verfahren zur Unterbrechung oder Milderung von Polydrogenabhängigkeits-Syndromen. Angemeldet am 30. Mai 1991, veröffentlicht am 3. Februar 1993, Anmelder: NDA International Inc, Erfinder: Howard S. Lotsof.‌
  • Patent US2817623A: Tabernanthine, ibogaine containing analgesic compositions. Angemeldet am 22. März 1956, veröffentlicht am 24. Dezember 1957, Anmelder: Ciba Pharmaceutical Products Inc, Erfinder: Jurg Adolf Schneider.‌
  • Patentanmeldung DE1902227A1: Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung. Angemeldet am 17. Januar 1969, veröffentlicht am 4. September 1969, Erfinder: Dominique Bocher, Claudio Naranjo.‌

faz.net

ibogainealliance.org

  • Dosing. In: ibogainealliance.org. Global Ibogain Therapy Alliance, abgerufen am 21. Februar 2017 (englisch).

ibogainedossier.com

lovdata.no

maps.org

  • Kroupa, Patrick K. and Wells, Hattie: Ibogaine in the 21st Century. In: maps. XV. Jahrgang, Nr. 1. Multidisciplinary Association for Psychedelic Studies, 2005, S. 21–25 (maps.org [PDF; abgerufen am 23. Januar 2015]).

nih.gov

ncbi.nlm.nih.gov

  • Koenig X, Kovar M, Boehm S, Sandtner W, Hilber K: Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. In: Addict Biol. 2012, doi:10.1111/j.1369-1600.2012.00447.x, PMID 22458604.
  • Paling FP, Andrews LM, Valk GD, Blom HJ: Life-threatening complications of ibogaine: three case reports. In: Neth J Med. 70. Jahrgang, Nr. 9, 2012, S. 422–4, PMID 23123541.
  • Alper K, Reith ME, Sershen H: Ibogaine and the inhibition of acetylcholinesterase. In: J Ethnopharmacol. 139. Jahrgang, Nr. 3, 2012, S. 879–82, doi:10.1016/j.jep.2011.12.006, PMID 22200647.
  • Dao-Yao He, Nancy N. H. McGough, Ajay Ravindranathan, Jerome Jeanblanc, Marian L. Logrip, Khanhky Phamluong, Patricia H. Janak, Dorit Ron: Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption. In: Journal of Neuroscience. Band 25, Nr. 3, 2005, S. 619–628, doi:10.1523/JNEUROSCI.3959-04.2005, PMID 15659598.
  • Hoelen DW, Spiering W, Valk GD: Long-QT syndrome induced by the antiaddiction drug ibogaine. In: N. Engl. J. Med. 360. Jahrgang, Nr. 3, 2009, S. 308–9, doi:10.1056/NEJMc0804248, PMID 19144953.
  • Bulling S, Schicker K, Zhang YW, et al.: The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. In: J. Biol. Chem. 287. Jahrgang, Nr. 22, 2012, S. 18524–34, doi:10.1074/jbc.M112.343681, PMID 22451652, PMC 3365767 (freier Volltext).
  • Bowen WD, Vilner BJ, Williams W, Bertha CM, Kuehne ME, Jacobson AE: Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity. In: Eur J Pharmacol. 279. Jahrgang, Nr. 1, 1995, S. R1–3, doi:10.1016/0014-2999(95)00247-i, PMID 7556375.
  • S.D. Glick: Ibogaine-like effects of noribogaine in rats. In: Brain Res. 713(1–2). Jahrgang, 1996, S. 294–7, PMID 8725004.
  • Arias HR, Rosenberg A, Targowska-Duda KM, et al.: Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states. In: Int. J. Biochem. Cell Biol. 42. Jahrgang, Nr. 9, 2010, S. 1525–35, PMID 20684041.
  • O.D. Taraschenko: Is antagonism of alpha3beta4 nicotinic receptors a strategy to reduce morphine dependence? In: Eur. J. Pharmacol. 513(3). Jahrgang, 2005, S. 207–18, PMID 15862802.
  • C.J. Pace: Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. In: Eur. J. Pharmacol. 492(2–3). Jahrgang, 2004, S. 159–67, PMID 15178360.

chem.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

puzzlepiece.org

redirecter.toolforge.org

  • Naranjo, Claudio: The healing journey: new approaches to consciousness. Pantheon Books, New York 1973, ISBN 0-394-48826-1, V, Ibogaine: Fantasy and Reality, S. 197–231 (ibogaine.desk.nl (Memento des Originals vom 4. Dezember 2008 im Internet Archive) [abgerufen am 10. Oktober 2010]).

sigmaaldrich.com

spektrum.de

web.archive.org